GHB compositions
OwnerMortimer Mamelakinventor
Life of this patent
Estimating the term…
Abstract
The invention provides a combination of sodium gamma-hydroxybutyrate (GHB) or a prodrug or an analog thereof, with a compound that inhibits the metabolism of the GHB or GHB analog in vivo, thus prolonging or enhancing the bioactivity thereof.
Claims50
A therapeutic method comprising administering to a mammal an amount of a compound of formula (I)
- wherein X is H, a pharmaceutically-acceptable cation or (C1-C4)alkyl, and Y is OH, (C1-C4)alkanoyloxy, (C1-C4)alkoxy, phenylacetoxy or benzyloxy, or X and Y together are a single bond, in conjunction with an amount of an inhibitor compound that interferes with the in vivo oxidation of the compound of formula (I) so as to prolong the therapeutic effect of the compound of formula (I).
A therapeutic method comprising administering to a mammal an amount of a compound of formula (II)
- wherein X is H, a pharmaceutically acceptable cation or CO2X represents an ester linkage to an OH group on an inhibitor compound, and Y is OH, (C1-C4)alkanoyloxy, phenylacetoxy or an ester linkage to a carboxylic acid group of an inhibitor compound, wherein the inhibitor compound interferes with the in vivo oxidation of the compound of formula (II) so as to prolong the therapeutic effect of the compound of formula (II).
A therapeutic method comprising administering to a mammal an amount of a compound of formula (III):
- wherein each Z is H or the moiety Y—CH2(CH2)2C(O)—, where at least one Z is Y—CH2(CH2)2C(O)—, wherein Y is OH, (C1-C4)alkoxy, (C1-C4)alkanoyloxy, phenylacetoxy or benzyloxy, and Q is H, CH2(CH2)2CO2X or a pharmaceutically acceptable cation, wherein X is H, (C1-C4)alkyl or a pharmaceutically acceptable cation.
A composition comprising an amount of a compound of formula (I) or formula (II) in combination with an amount of one or more inhibitor compounds that act so as to interfere with the in vivo oxidation of the compound of formula (I) or formula (II), respectively.
A composition comprising an amount of a compound of formula (III) in combination with a pharmaceutically acceptable carrier.
A compound of formula (II)
- wherein X is H, a pharmaceutically acceptable cation or CO2X represents an ester linkage to an OH group on an inhibitor compound, and Y is OH, (C1-C4)alkanoyloxy, phenylacetoxy or an ester linkage to a carboxylic acid group of an inhibitor compound, wherein the inhibitor compound interferes with the in vivo oxidation of the compound of formula (II) so as to prolong the therapeutic effect of the compound of formula (II).
A compound of formula (III):
- wherein each Z is H or the moiety Y—CH2(CH2)2C(O)—, where at least one Z is Y—CH2(CH2)2C(O)—, wherein Y is OH, (C1-C4)alkoxy, (C1-C4)alkanoyloxy, phenylacetoxy or benzyloxy, and Q is H, CH2(CH2)2CO2X or a pharmaceutically acceptable cation, wherein X is H, (C1-C4)alkyl or a pharmaceutically acceptable cation.
Dependencies are inferred from the claim text.